Tag: Ekterly

Affecting approximately 1 in 50,000 people, hereditary angioedema (HAE) is a rare genetic condition that causes unpredictable and potentially life-threatening episodes of swelling. Recent breakthroughs in HAE treatment have led to several new therapies hitting the market, including Andembry, Ekterly, and Dawnzera, dramatically expanding the options for patients managing this lifelong disease.

Hereditary angioedema (HAE) affects an estimated 6,000 people in the United States, and the treatment landscape has expanded significantly with the approval of oral medications. The answer to "What is the pill for hereditary angioedema?" depends on the purpose of the medication: prevention of attacks versus on-demand treatment.